Philadelphia Veterans Affairs Medical Center
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT01603381
The investigators intend to assess the following:
* the efficacy of CBTi in treating insomnia during recovery, * does a family history of alcoholism moderate the insomnia symptoms, * does an improvement in insomnia lead to a decrease in impulsivity.
Looking for future studies?
Notify Me18 year–65 year
Male
Interventional
Not applicable
Philadelphia, Pennsylvania, 19104, United States
The primary goals of this pilot study are the following:
a) to assess for the difference in improvement insomnia, after 8 weeks of treatment with recommended CBTi, in Veterans with alcohol dependence during early recovery,
The secondary goals include the following:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Behavioral management of insomnia
Time frame: 8 weeks.
There will be post-treatment follow up at 3 months and 6 months.
Time frame: 8 weeks.
There will be post-study follow-up at 3 months and 6 months also.
Corporal Michael J. Crescenz VA Medical Center
Fed
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05956886
Dyssomnias, Glucose Metabolism Disorders
Newark, Delaware, United States
View Trial DetailsNCT03665337
Delayed Sleep Phase, Dyssomnias
San Francisco, California, United States
View Trial DetailsNCT07417163
Cirrhosis, Dyssomnias
Boston, Massachusetts, United States
View Trial DetailsNCT04936321
Brain Diseases, Central Nervous System Diseases
Seattle, Washington, United States
View Trial Details